Search Result

Results for "

ferroptosis+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (3) Carbonic Anhydrase (1) Drug Derivative (1) Endogenous Metabolite (5) Environmental Pollutants (1) Ferroptosis (43) Fluorescent Dye (1) Fungal (2) Glutathione Peroxidase (4) Isotope-Labeled Compounds (2) JNK (5) Keap1-Nrf2 (1) MDM-2/p53 (2) Prostaglandin Receptor (2) PROTACs (1) Reactive Oxygen Species (ROS) (10) Reference Standards (3) SLC39 (Zinc Transporter) (1) VDAC (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (7) Endocrinology (2) Inflammation/Immunology (10) Metabolic Disease (7) Neurological Disease (11)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Antioxidants (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100579

Ferrostatin-1 Maximum Cited Publications 1548 Publications Verification Fer-1	Ferroptosis Fungal	Cancer
Ferrostatin-1 (Fer-1), a potent and selective *ferroptosis* inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC₅₀=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .

HY-12726

Liproxstatin-1 230+ Cited Publications	Ferroptosis	Cancer
Liproxstatin-1 is a potent *ferroptosis* inhibitor and inhibits ferroptotic cell death (IC₅₀=22 nM) .

HY-12041

SP600125 580+ Cited Publications	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC₅₀s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent *ferroptosis* inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

HY-Y0172

Butylated hydroxytoluene 4 Publications Verification	Environmental Pollutants Endogenous Metabolite Ferroptosis	Cancer
Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a *Ferroptosis* inhibitor .

HY-138153

JKE-1674 5+ Cited Publications	Glutathione Peroxidase Ferroptosis	Cancer
JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by *ferroptosis* inhibitors .

HY-114395

NVS-ZP7-4 5+ Cited Publications	Ferroptosis SLC39 (Zinc Transporter)	Inflammation/Immunology
NVS-ZP7-4 is an inhibitor of the zinc transporter SLC39A7 (ZIP7) and indicates ER zinc levels. ZIP7 is an active molecular node in the Notch pathway and mediates *ferroptosis. NVS-ZP7-4 induces ER stress* and exerts a certain ferroptosis-inhibiting effect, reduces Erastin (HY-15763)-induced cell death .

HY-112909

UAMC-3203 5+ Cited Publications FXT-001	Ferroptosis	Neurological Disease Metabolic Disease Cancer
UAMC-3203 is a potent and selective *Ferroptosis* inhibitor with an IC₅₀ of 12 nM.

HY-12726A

Liproxstatin-1 hydrochloride 230+ Cited Publications	Ferroptosis	Cancer
Liproxstatin-1 hydrochloride is a potent *ferroptosis* inhibitor and inhibits ferroptotic cell death (IC₅₀=22 nM) .

HY-163897

PROTAC NCOA4 degrader-1	PROTACs Ferroptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
PROTAC NCOA4 degrader-1 is a VHL-based PROTAC NCOA4 degrader. PROTAC NCOA4 degrader-1 is a *ferroptosis* inhibitor. PROTAC NCOA4 degrader-1 reduces Fe ²⁺ elevation, ROS production, MDA content and PTGS2 mRNA expression. PROTAC NCOA4 degrader-1 ameliorates liver damage in a CCl₄-induced acute liver injury model. PROTAC NCOA4 degrader-1 can be used for the researches of inflammation and immunology. (Pink: NCOA4 ligand (HY-149457). Black: linker (HY-163903). Blue: VHL ligand (HY-138678B)) .

HY-112909A

UAMC-3203 hydrochloride 5+ Cited Publications FXT-001 hydrochloride	Ferroptosis	Neurological Disease Metabolic Disease Cancer
UAMC-3203 hydrochloride is a potent and selective *Ferroptosis* inhibitor with an IC₅₀ of 12 nM .

HY-B0774

Seratrodast 4 Publications Verification AA 2414	Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and *ferroptosis* inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .

HY-N11849

Moracin N 2 Publications Verification	Ferroptosis Glutathione Peroxidase	Neurological Disease
Moracin N is a *ferroptosis* inhibitor that can be isolated from mulberry leaf. Moracin N exerts neuroprotective activity through preventing from oxidative stress .

HY-Y0172S

Butylated hydroxytoluene-d21	Ferroptosis Endogenous Metabolite	Cancer
Butylated hydroxytoluene-d₂₁ is the deuterium labeled Butylated hydroxytoluene . Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a Ferroptosis inhibitor .

HY-W002942

Ferroptosis-IN-21 1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline	Ferroptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
Ferroptosis-IN-21 is a *ferroptosis* inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .

HY-152093

YL-939	Ferroptosis	Cancer
YL-939 is a potent *ferroptosis* inhibitor. YL-939 inhibits ferroptosis by targeting the PHB2/ferritin/iron axis .

HY-Y0172S2

Butylated hydroxytoluene-d3	Ferroptosis Endogenous Metabolite	Cancer
Butylated hydroxytoluene-d₃ is the deuterium labeled Butylated hydroxytoluene . Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a Ferroptosis inhibitor .

HY-163654

Ferroptosis-IN-8	Ferroptosis	Cancer
Ferroptosis-IN-8 is a potent *ferroptosis* inhibitor with an EC₅₀ of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis .

HY-161460

Ferroptosis-IN-7	Ferroptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease
Ferroptosis-IN-7(Compound 26) is a *ferroptosis* inhibitor which can restore cell viability, reduce iron accumulation and scavenge reactive oxygen species. Ferroptosis-IN-7 can be used for vascular diseases research .

HY-173313

Ferroptosis-IN-19	Ferroptosis	Cardiovascular Disease
Ferroptosis-IN-19 (compound C18) is a strong cellular ferroptosis inhibitor with an IC₅₀ value of 0.097 μM. Ferroptosis-IN-19 shows high metabolic stability and favorable BBB permeability prediction. Ferroptosis-IN-19 has in vivo neuroprotection against ischemic brain injury in mice .

HY-B0774R

Seratrodast (Standard) AA 2414 (Standard)	Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reference Standards Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Seratrodast (Standard) is the analytical standard of Seratrodast. This product is intended for research and analytical applications. Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and *ferroptosis* inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .

HY-Y0172S1

Butylated hydroxytoluene-d24	Ferroptosis Endogenous Metabolite	Cancer
Butylated hydroxytoluene-d₂₄ is the deuterium labeled Butylated hydroxytoluene . Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a Ferroptosis inhibitor .

HY-Y0172R

Butylated hydroxytoluene (Standard)	Reference Standards Ferroptosis Endogenous Metabolite	Cancer
Butylated hydroxytoluene (Standard) is the analytical standard of Butylated hydroxytoluene. This product is intended for research and analytical applications. Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a *Ferroptosis* inhibitor .

HY-170509

Ferroptosis-IN-17	Ferroptosis Glutathione Peroxidase	Cardiovascular Disease Neurological Disease Cancer
Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC₅₀ value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases .

HY-176212

Ferroptosis-IN-20	Ferroptosis VDAC Reactive Oxygen Species (ROS)	Inflammation/Immunology
Ferroptosis-IN-20 (Compound 34a) is a *Ferroptosis* inhibitor (EC₅₀: 24.2 nM) targeting voltage-dependent anion channel (VDAC). Ferroptosis-IN-20 inhibits VDAC oligomerization and lipid peroxidation. Ferroptosis-IN-20 reduces content of ROS, attenuates TFR1-mediated iron uptake, inhibits Fe ²⁺ level and restores glutathione (GSH) level. Ferroptosis-IN-20 alleviates Folic acid (HY-16637)-induced acute kidney injury (AKI) .

HY-175869

Ferroptosis-IN-22	Ferroptosis	Metabolic Disease Inflammation/Immunology
Ferroptosis-IN-22 is a selective *ferroptosis* inhibitor by targeting NCOA4 and disrupting its interaction with ferritin with an EC₅₀ of 520 nM and a K_d of 0.78 μM. Ferroptosis-IN-22 has a strong inhibitory activity against ferroptosis induced by multiple ferroptosis inducers (RSL3 (HY-100218A), Erastin (HY-15763), ML210 (HY-100003), FIN56 (HY-103087)), but does not inhibit necrosis induced by H₂O₂ or apoptosis induced by STS (HY-15141). Ferroptosis-IN-22 effectively ameliorates Concanavalin A (HY-P2149)-induced acute liver injury. Ferroptosis-IN-22 can be used for the study of ferroptosis-related diseases .

HY-156066

Ferrostatin-1 diyne Fer-1 diyne	Ferroptosis	Cancer
Ferrostatin-1 diyne (Fer-1 diyne) (compound 2) is a *ferroptosis* inhibitor that accumulates in lysosomes, mitochondria, and endoplasmic reticulum in cells, but its inhibition of ferroptosis is not dependent on the activity of lysosomes and mitochondria.

HY-149723

Ferroptosis-IN-5	Ferroptosis	Cancer
Ferroptosis-IN-5 (compound 9c) is a *ferroptosis* inhibitor with iron-chelating and reactive oxygen species (ROS) scavenging activities .

HY-163718

Ferroptosis-IN-9	Ferroptosis	Neurological Disease
Ferroptosis-IN-9 (compound 23b) is a ferroptosis inhibitor with an IC₅₀ value of >30uM for hERG inhibition. Ferroptosis-IN-9 is a ROS scavenger. Ferroptosis-IN-9 can be used in neurodegenerative disease research .

HY-170675

Ferroptosis-IN-13	Ferroptosis	Cancer
Ferroptosis-IN-13 (compound NY-26) is a *ferroptosis* inhibitor. Ferroptosis-IN-13 inhibits RSL3(HY-100218A)-induced ferroptosis in 786-O cells with an EC₅₀ value of 62 nM .

HY-12726S1

Liproxstatin-1-15N	Isotope-Labeled Compounds	Cancer
Liproxstatin-1- ¹⁵N is the ¹⁵N labled Liproxstatin-1 (HY-12726). Liproxstatin-1 is a potent *ferroptosis* inhibitor and inhibits ferroptotic cell death (IC₅₀=22 nM) .

HY-12726S

Liproxstatin-1-13C6	Isotope-Labeled Compounds	Cancer
Liproxstatin-1- ¹³C₆ is the ¹³C labled Liproxstatin-1 (HY-12726). Liproxstatin-1 is a potent *ferroptosis* inhibitor and inhibits ferroptotic cell death (IC₅₀=22 nM) .

HY-149719

Ferroptosis-IN-4	Ferroptosis	Metabolic Disease
Ferroptosis-IN-4 (compound 6k) is a *ferroptosis* inhibitor with EC₅₀ value of 20 μM. Ferroptosis-IN-4 has no obvious cytotoxicity. Ferroptosis-IN-4 has a protective effect in glycerol-induced RM-AKI mice with alleviating kidney dysfunction .

HY-159567

Ferroptosis-IN-11	Ferroptosis	Cardiovascular Disease Neurological Disease
Ferroptosis-IN-11 (compound 43) is a *ferroptosis* inhibitor. Ferroptosis-IN-11 can inhibit Erastin (HY-15763) induced ferroptosis in HT-1080 human fibroblasts (EC₅₀=36 nM). Ferroptosis-IN-11 can be used in the study of cardiovascular disease and neurodegeneration .

HY-149670

Ferroptosis-IN-3	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-3 (Compound 25) is a *ferroptosis* inhibitor. Ferroptosis-IN-3 inhibits RSL3-induced ferroptosis (EC₅₀: 8.6?nM in HT-1080?cells). Ferroptosis-IN-3 scavenges DPPH and ABTS radicals (EC₅₀: 3.94?and 6.3 μM respectively). Ferroptosis-IN-3 decreases lipid peroxidation .

HY-12041R

SP600125 (Standard)	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 (Standard) is the analytical standard of SP600125. This product is intended for research and analytical applications. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

HY-170959

NYY-6a	Ferroptosis	Neurological Disease Metabolic Disease
NYY-6a is a *Ferroptosis* inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC₅₀s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a *ferroptosis* inhibitor. Ferroptosis-IN-12 exhibits effective *ferroptosis* inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-178475

CA IX/GPX4-IN-1	Carbonic Anhydrase Glutathione Peroxidase Ferroptosis	Cancer
CA IX/GPX4-IN-1 (Compound 22abcb) is a dual targeted inhibitor of CA IX and GPX4 activity. CA IX/GPX4-IN-1 can effectively kill SUM159PT cells (IC₅₀ = 416 nM) by inducing iron death under hypoxic conditions. CA IX/GPX4-IN-1 has an IC₅₀ of 663 nM to CA IX in SUM159PT-CAIX-FL cells. CA IX/GPX4-IN-1 can significantly inhibit tumor growth and can be reversed by *ferroptosis* inhibitors. CA IX/GPX4-IN-1 can be used for research on breast cancer and other cancers .

HY-181548

YL3147	Ferroptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease
YL3147 is a *ferroptosis* inhibitor. YL3147 also acts as a radical-trapping antioxidant that directly prevents the spread of lipid peroxidation and blocks ferroptosis. YL3147 exerts significant cardioprotective effects in mouse cardiomyopathy models. YL3147 can be used in studies related to cardiomyopathy .

HY-183589

Ferroptosis-IN-26	Ferroptosis Reactive Oxygen Species (ROS)	Metabolic Disease
Ferroptosis-IN-26 is a CEPT1-targeting *ferroptosis* inhibitor. Ferroptosis-IN-26 enhances CEPT1-dependent phosphatidylcholine remodeling to enrich cellular membranes with monounsaturated fatty acid-containing phosphatidylcholine (PC-MUFA). Ferroptosis-IN-26 suppresses lipid peroxidation. Ferroptosis-IN-26 can be used for the research of acute liver injury .

HY-183289

Ferroptosis-IN-25	Ferroptosis Reactive Oxygen Species (ROS) Drug Derivative	Neurological Disease
Ferroptosis-IN-25, Trolox (HY-101445) derivative, is a selective *ferroptosis* inhibitor. Ferroptosis-IN-25 selectively inhibits ferroptosis by scavenging ROS and suppressing lipid peroxidation independently of glutathion. Ferroptosis-IN-25 reduces corneal neovascularization and edema in murine corneal alkali burn models via topical administration.Ferroptosis-IN-25 can be used for the research of ocular surface diseases .

HY-185056

Ferfluor-1	Ferroptosis Fluorescent Dye	Cardiovascular Disease Neurological Disease
Ferfluor-1 is a *Ferroptosis* inhibitor (EC₅₀ of 57 nM in HT108 cells; EC₅₀ of 75 nM in OS-RC-2 cells; EC₅₀ of 2.3 nM in SH-SY5Y neuroblastoma cells), and ratiometric photoluminescent probe with blood-brain barrier permeability. Ferfluor-1 is a specific indicator for the fluctuation of Ferroptosis. Ferfluor-1 alleviates brain disorder diseases of in vivo stroke and PD models .

HY-182390

Ferroptosis-IN-24	Ferroptosis Reactive Oxygen Species (ROS) Keap1-Nrf2	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Ferroptosis-IN-24 is a non-classical *ferroptosis* inhibitor capable of crossing the blood-brain barrier, with nanomolar inhibitory activity against ferroptosis induced by RSL3 (HY-100218A) and Erastin (HY-15763). Ferroptosis-IN-24 alleviates oxidative stress, reduces lipid peroxidation accumulation, and restores redox homeostasis. Ferroptosis-IN-24 is applicable to research related to cerebral ischemia-reperfusion injury and acute liver injury .

HY-12041G

SP600125	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC₅₀s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

HY-100579R

Ferrostatin-1 (Standard) Fer-1 (Standard)	Ferroptosis Reference Standards Fungal	Cancer
Ferrostatin-1 (Standard) is the analytical standard of Ferrostatin-1 (HY-100579). This product is intended for research and analytical applications. Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .

Cat. No.	Product Name	Type

HY-12041G

SP600125

Fluorescent Dyes

SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC₅₀s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

Cat. No.	Product Name	Type

HY-12041G

SP600125

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0172

Butylated hydroxytoluene 4 Publications Verification	Structural Classification Monophenols Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	Environmental Pollutants Endogenous Metabolite Ferroptosis
Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a *Ferroptosis* inhibitor .

HY-N11849

Moracin N 2 Publications Verification	Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Ferroptosis Glutathione Peroxidase
Moracin N is a *ferroptosis* inhibitor that can be isolated from mulberry leaf. Moracin N exerts neuroprotective activity through preventing from oxidative stress .

HY-Y0172R

Butylated hydroxytoluene (Standard)	Structural Classification Monophenols Leguminosae Phenols Plants Endogenous metabolite Glycyrrhiza uralensis Fisch. Source Classification	Reference Standards Ferroptosis Endogenous Metabolite
Butylated hydroxytoluene (Standard) is the analytical standard of Butylated hydroxytoluene. This product is intended for research and analytical applications. Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a *Ferroptosis* inhibitor .

Cat. No.	Product Name	Chemical Structure

HY-Y0172S

Butylated hydroxytoluene-d21
Butylated hydroxytoluene-d₂₁ is the deuterium labeled Butylated hydroxytoluene . Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a Ferroptosis inhibitor .

HY-Y0172S2

Butylated hydroxytoluene-d3
Butylated hydroxytoluene-d₃ is the deuterium labeled Butylated hydroxytoluene . Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a Ferroptosis inhibitor .

HY-Y0172S1

Butylated hydroxytoluene-d24
Butylated hydroxytoluene-d₂₄ is the deuterium labeled Butylated hydroxytoluene . Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a Ferroptosis inhibitor .

HY-12726S1

Liproxstatin-1-15N
Liproxstatin-1- ¹⁵N is the ¹⁵N labled Liproxstatin-1 (HY-12726). Liproxstatin-1 is a potent *ferroptosis* inhibitor and inhibits ferroptotic cell death (IC₅₀=22 nM) .

HY-12726S

Liproxstatin-1-13C6
Liproxstatin-1- ¹³C₆ is the ¹³C labled Liproxstatin-1 (HY-12726). Liproxstatin-1 is a potent *ferroptosis* inhibitor and inhibits ferroptotic cell death (IC₅₀=22 nM) .

Cat. No.	Product Name		Classification

HY-178475

CA IX/GPX4-IN-1		Alkynes
CA IX/GPX4-IN-1 (Compound 22abcb) is a dual targeted inhibitor of CA IX and GPX4 activity. CA IX/GPX4-IN-1 can effectively kill SUM159PT cells (IC₅₀ = 416 nM) by inducing iron death under hypoxic conditions. CA IX/GPX4-IN-1 has an IC₅₀ of 663 nM to CA IX in SUM159PT-CAIX-FL cells. CA IX/GPX4-IN-1 can significantly inhibit tumor growth and can be reversed by *ferroptosis* inhibitors. CA IX/GPX4-IN-1 can be used for research on breast cancer and other cancers .

Cat. No.	Product Name		Classification

HY-Y0172

Butylated hydroxytoluene 4 Publications Verification		Antioxidants
Butylated hydroxytoluene is an antioxidant widely used in foods and in food-related products . Butylated hydroxytoluene is a *Ferroptosis* inhibitor .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12041G

SP600125	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC₅₀s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ferroptosis+inhibitor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products